{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,29]],"date-time":"2026-08-29T06:17:03Z","timestamp":1787984223287,"version":"build-2784847793"},"reference-count":30,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2026,8,28]]},"DOI":"10.7759\/cureus.115381","type":"journal-article","created":{"date-parts":[[2026,8,29]],"date-time":"2026-08-29T05:35:53Z","timestamp":1787981753000},"source":"Crossref","is-referenced-by-count":0,"title":["Comprehensive Genomic Profiling Across Diverse Tumors Using the OncoIndx\u00ae Assay: Real-World Insights From an Indian Cohort"],"prefix":"10.7759","author":[{"given":"Pramod K","family":"Julka","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Deepika","family":"Arya","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Afnan","family":"Bhasir","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Trinica","family":"George","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ganesh","family":"Divekar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gowhar","family":"Shafi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.1186\/s13073-019-0703-1","article-title":"Molecular profiling for precision cancer therapies","volume":"12","author":"Malone ER","year":"2020","unstructured":"Malone ER, Oliva M, Sabatini PJ, Stockley TL, Siu LL. Molecular profiling for precision cancer therapies. Genome Med. 2020, 12:8. 10.1186\/s13073-019-0703-1","journal-title":"Genome Med"},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.1038\/nm0817-1004c","article-title":"Erratum: Mutational landscape of metastatic cancer revealed from prospective clinical sequencing of 10,000 patients","volume":"23","author":"Zehir A","year":"2017","unstructured":"Zehir A, Benayed R, Shah RH, et al.. Erratum: Mutational landscape of metastatic cancer revealed from prospective clinical sequencing of 10,000 patients. Nat Med. 2017, 23:1004. 10.1038\/nm0817-1004c","journal-title":"Nat Med"},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.1001\/jamaoncol.2018.1660","article-title":"Estimation of the percentage of US patients with cancer who benefit from genome-driven oncology","volume":"4","author":"Marquart J","year":"2018","unstructured":"Marquart J, Chen EY, Prasad V. Estimation of the percentage of US patients with cancer who benefit from genome-driven oncology. JAMA Oncol. 2018, 4:1093-8. 10.1001\/jamaoncol.2018.1660","journal-title":"JAMA Oncol"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.1038\/nbt.2696","article-title":"Development and validation of a clinical cancer genomic profiling test based on massively parallel DNA sequencing","volume":"31","author":"Frampton GM","year":"2013","unstructured":"Frampton GM, Fichtenholtz A, Otto GA, et al.. Development and validation of a clinical cancer genomic profiling test based on massively parallel DNA sequencing. Nat Biotechnol. 2013, 31:1023-31. 10.1038\/nbt.2696","journal-title":"Nat Biotechnol"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.21.02767","article-title":"Somatic genomic testing in patients with metastatic or advanced cancer: ASCO Provisional Clinical Opinion","volume":"40","author":"Chakravarty D","year":"2022","unstructured":"Chakravarty D, Johnson A, Sklar J, et al.. Somatic genomic testing in patients with metastatic or advanced cancer: ASCO Provisional Clinical Opinion. J Clin Oncol. 2022, 40:1231-58. 10.1200\/JCO.21.02767","journal-title":"J Clin Oncol"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.1038\/nature11412","article-title":"Comprehensive molecular portraits of human breast tumours","volume":"490","year":"2012","unstructured":"Comprehensive molecular portraits of human breast tumours. Nature. 2012, 490.61-70. 10.1038\/nature11412","journal-title":"Nature"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.1038\/s41588-018-0312-8","article-title":"Tumor mutational load predicts survival after immunotherapy across multiple cancer types","volume":"51","author":"Samstein RM","year":"2019","unstructured":"Samstein RM, Lee CH, Shoushtari AN, et al.. Tumor mutational load predicts survival after immunotherapy across multiple cancer types. Nat Genet. 2019, 51:202-6. 10.1038\/s41588-018-0312-8","journal-title":"Nat Genet"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.1126\/science.aan6733","article-title":"Mismatch repair deficiency predicts response of solid tumors to PD-1 blockade","volume":"357","author":"Le DT","year":"2017","unstructured":"Le DT, Durham JN, Smith KN, et al.. Mismatch repair deficiency predicts response of solid tumors to PD-1 blockade. Science. 2017, 357:409-13. 10.1126\/science.aan6733","journal-title":"Science"},{"key":"ref9","unstructured":"FoundationOne\u00ae CDx. (2017). Accessed. 2026: https:\/\/www.accessdata.fda.gov\/cdrh_docs\/pdf17\/P170019S014C.pdf."},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.1186\/s13073-017-0424-2","article-title":"Analysis of 100,000 human cancer genomes reveals the landscape of tumor mutational burden","volume":"9","author":"Chalmers ZR","year":"2017","unstructured":"Chalmers ZR, Connelly CF, Fabrizio D, et al.. Analysis of 100,000 human cancer genomes reveals the landscape of tumor mutational burden. Genome Med. 2017, 9:34. 10.1186\/s13073-017-0424-2","journal-title":"Genome Med"},{"key":"ref11","doi-asserted-by":"publisher","DOI":"10.1016\/j.jmoldx.2016.10.002","article-title":"Standards and guidelines for the interpretation and reporting of sequence variants in cancer: a joint consensus recommendation of the Association for Molecular Pathology, American Society of Clinical Oncology, and College of American Pathologists","volume":"19","author":"Li MM","year":"2017","unstructured":"Li MM, Datto M, Duncavage EJ, et al.. Standards and guidelines for the interpretation and reporting of sequence variants in cancer: a joint consensus recommendation of the Association for Molecular Pathology, American Society of Clinical Oncology, and College of American Pathologists. J Mol Diagn. 2017, 19:4-23. 10.1016\/j.jmoldx.2016.10.002","journal-title":"J Mol Diagn"},{"key":"ref12","doi-asserted-by":"publisher","DOI":"10.1038\/nrc.2017.7","article-title":"Liquid biopsies come of age: towards implementation of circulating tumour DNA","volume":"17","author":"Wan JC","year":"2017","unstructured":"Wan JC, Massie C, Garcia-Corbacho J, et al.. Liquid biopsies come of age: towards implementation of circulating tumour DNA. Nat Rev Cancer. 2017, 17:223-38. 10.1038\/nrc.2017.7","journal-title":"Nat Rev Cancer"},{"key":"ref13","doi-asserted-by":"publisher","DOI":"10.1158\/2159-8290.CD-15-1483","article-title":"Clinical applications of circulating tumor cells and circulating tumor DNA as liquid biopsy","volume":"6","author":"Alix-Panabi\u00e8res C","year":"2016","unstructured":"Alix-Panabi\u00e8res C, Pantel K. Clinical applications of circulating tumor cells and circulating tumor DNA as liquid biopsy. Cancer Discov. 2016, 6:479-91. 10.1158\/2159-8290.CD-15-1483","journal-title":"Cancer Discov"},{"key":"ref14","doi-asserted-by":"publisher","DOI":"10.3390\/cancers16193415","article-title":"Clinical and technical validation of OncoIndx\u00ae assay-a comprehensive genome profiling assay for pan-cancer investigations","volume":"16","author":"Ramesh A","year":"2024","unstructured":"Ramesh A, Bharde A, D'Souza A, et al.. Clinical and technical validation of OncoIndx\u00ae assay-a comprehensive genome profiling assay for pan-cancer investigations. Cancers (Basel). 2024, 16:3415. 10.3390\/cancers16193415","journal-title":"Cancers (Basel)"},{"key":"ref15","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-022-01717-2","article-title":"Delivering precision oncology to patients with cancer","volume":"28","author":"Mateo J","year":"2022","unstructured":"Mateo J, Steuten L, Aftimos P, et al.. Delivering precision oncology to patients with cancer. Nat Med. 2022, 28:658-65. 10.1038\/s41591-022-01717-2","journal-title":"Nat Med"},{"key":"ref16","doi-asserted-by":"publisher","DOI":"10.3390\/biology12070997","article-title":"Next-generation sequencing technology: current trends and advancements","volume":"12","author":"Satam H","year":"2023","unstructured":"Satam H, Joshi K, Mangrolia U, et al.. Next-generation sequencing technology: current trends and advancements. Biology (Basel). 2023, 12:997. 10.3390\/biology12070997","journal-title":"Biology (Basel)"},{"key":"ref17","doi-asserted-by":"publisher","DOI":"10.7759\/cureus.101804","article-title":"Comprehensive genomic profiling across diverse solid tumors: a real-world experience from India with FoundationOne\u00aeCDx testing","volume":"18","author":"Julka PK","year":"2026","unstructured":"Julka PK, Arya D, Gupta S. Comprehensive genomic profiling across diverse solid tumors: a real-world experience from India with FoundationOne\u00aeCDx testing. Cureus. 2026, 18:e101804. 10.7759\/cureus.101804","journal-title":"Cureus"},{"key":"ref18","doi-asserted-by":"publisher","DOI":"10.1126\/science.1235122","article-title":"Cancer genome landscapes","volume":"339","author":"Vogelstein B","year":"2013","unstructured":"Vogelstein B, Papadopoulos N, Velculescu VE, Zhou S, Diaz LA Jr, Kinzler KW. Cancer genome landscapes. Science. 2013, 339:1546-58. 10.1126\/science.1235122","journal-title":"Science"},{"key":"ref19","doi-asserted-by":"publisher","DOI":"10.1101\/cshperspect.a001008","article-title":"TP53 mutations in human cancers: origins, consequences, and clinical use","volume":"2","author":"Olivier M","year":"2010","unstructured":"Olivier M, Hollstein M, Hainaut P. TP53 mutations in human cancers: origins, consequences, and clinical use. Cold Spring Harb Perspect Biol. 2010, 2:a001008. 10.1101\/cshperspect.a001008","journal-title":"Cold Spring Harb Perspect Biol"},{"key":"ref20","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1813904","article-title":"Alpelisib for PIK3CA-mutated, hormone receptor-positive advanced breast cancer","volume":"380","author":"Andr\u00e9 F","year":"2019","unstructured":"Andr\u00e9 F, Ciruelos E, Rubovszky G, et al.. Alpelisib for PIK3CA-mutated, hormone receptor-positive advanced breast cancer. N Engl J Med. 2019, 380:1929-40. 10.1056\/NEJMoa1813904","journal-title":"N Engl J Med"},{"key":"ref21","doi-asserted-by":"publisher","DOI":"10.1016\/j.cell.2018.03.035","article-title":"Oncogenic signaling pathways in the Cancer Genome Atlas","volume":"173","author":"Sanchez-Vega F","year":"2018","unstructured":"Sanchez-Vega F, Mina M, Armenia J, et al.. Oncogenic signaling pathways in the Cancer Genome Atlas. Cell. 2018, 173:321-37.e10. 10.1016\/j.cell.2018.03.035","journal-title":"Cell"},{"key":"ref22","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2017.72.7107","article-title":"Phosphatidylinositol 3-kinase \u03b1-selective inhibition with alpelisib (BYL719) in PIK3CA-altered solid tumors: results from the first-in-human study","volume":"36","author":"Juric D","year":"2018","unstructured":"Juric D, Rodon J, Tabernero J, et al.. Phosphatidylinositol 3-kinase \u03b1-selective inhibition with alpelisib (BYL719) in PIK3CA-altered solid tumors: results from the first-in-human study. J Clin Oncol. 2018, 36:1291-9. 10.1200\/JCO.2017.72.7107","journal-title":"J Clin Oncol"},{"key":"ref23","doi-asserted-by":"publisher","DOI":"10.3390\/diagnostics13091619","article-title":"Comprehensive genomic profiling and therapeutic implications for patients with advanced cancers: the experience of an academic hospital","volume":"13","author":"Teuwen LA","year":"2023","unstructured":"Teuwen LA, Roets E, D'Hoore P, Pauwels P, Prenen H. Comprehensive genomic profiling and therapeutic implications for patients with advanced cancers: the experience of an academic hospital. Diagnostics (Basel). 2023, 13:1619. 10.3390\/diagnostics13091619","journal-title":"Diagnostics (Basel)"},{"key":"ref24","doi-asserted-by":"publisher","DOI":"10.1111\/cas.13837","article-title":"Next generation sequencing-based gene panel tests for the management of solid tumors","volume":"110","author":"Nagahashi M","year":"2019","unstructured":"Nagahashi M, Shimada Y, Ichikawa H, Kameyama H, Takabe K, Okuda S, Wakai T. Next generation sequencing-based gene panel tests for the management of solid tumors. Cancer Sci. 2019, 110:6-15. 10.1111\/cas.13837","journal-title":"Cancer Sci"},{"key":"ref25","doi-asserted-by":"publisher","DOI":"10.1038\/nature12634","article-title":"Mutational landscape and significance across 12 major cancer types","volume":"502","author":"Kandoth C","year":"2013","unstructured":"Kandoth C, McLellan MD, Vandin F, et al.. Mutational landscape and significance across 12 major cancer types. Nature. 2013, 502:333-9. 10.1038\/nature12634","journal-title":"Nature"},{"key":"ref26","doi-asserted-by":"publisher","DOI":"10.1016\/j.cell.2017.07.029","article-title":"The PI3K pathway in human disease","volume":"170","author":"Fruman DA","year":"2017","unstructured":"Fruman DA, Chiu H, Hopkins BD, Bagrodia S, Cantley LC, Abraham RT. The PI3K pathway in human disease. Cell. 2017, 170:605-35. 10.1016\/j.cell.2017.07.029","journal-title":"Cell"},{"key":"ref27","doi-asserted-by":"publisher","DOI":"10.1126\/science.aam7344","article-title":"PARP inhibitors: synthetic lethality in the clinic","volume":"355","author":"Lord CJ","year":"2017","unstructured":"Lord CJ, Ashworth A. PARP inhibitors: synthetic lethality in the clinic. Science. 2017, 355:1152-8. 10.1126\/science.aam7344","journal-title":"Science"},{"key":"ref28","doi-asserted-by":"publisher","DOI":"10.1038\/s41576-018-0071-5","article-title":"Current and future perspectives of liquid biopsies in genomics-driven oncology","volume":"20","author":"Heitzer E","year":"2019","unstructured":"Heitzer E, Haque IS, Roberts CE, Speicher MR. Current and future perspectives of liquid biopsies in genomics-driven oncology. Nat Rev Genet. 2019, 20:71-88. 10.1038\/s41576-018-0071-5","journal-title":"Nat Rev Genet"},{"key":"ref29","doi-asserted-by":"publisher","DOI":"10.1126\/scitranslmed.3007094","article-title":"Detection of circulating tumor DNA in early- and late-stage human malignancies","volume":"6","author":"Bettegowda C","year":"2014","unstructured":"Bettegowda C, Sausen M, Leary RJ, et al.. Detection of circulating tumor DNA in early- and late-stage human malignancies. Sci Transl Med. 2014, 6:224ra24. 10.1126\/scitranslmed.3007094","journal-title":"Sci Transl Med"},{"key":"ref30","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1113205","article-title":"Intratumor heterogeneity and branched evolution revealed by multiregion sequencing","volume":"366","author":"Gerlinger M","year":"2012","unstructured":"Gerlinger M, Rowan AJ, Horswell S, et al.. Intratumor heterogeneity and branched evolution revealed by multiregion sequencing. N Engl J Med. 2012, 366:883-92. 10.1056\/NEJMoa1113205","journal-title":"N Engl J Med"}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/510204-comprehensive-genomic-profiling-across-diverse-tumors-using-the-oncoindx-assay-real-world-insights-from-an-indian-cohort","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,29]],"date-time":"2026-08-29T05:35:54Z","timestamp":1787981754000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/510204-comprehensive-genomic-profiling-across-diverse-tumors-using-the-oncoindx-assay-real-world-insights-from-an-indian-cohort"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8,28]]},"references-count":30,"URL":"https:\/\/doi.org\/10.7759\/cureus.115381","relation":{},"ISSN":["2168-8184"],"issn-type":[{"value":"2168-8184","type":"print"}],"subject":[],"published":{"date-parts":[[2026,8,28]]}}}